FOLFOXIRI (IRINOTECAN, OXALIPLATIN, INFUSIONAL 5FU/LV) VS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS AFTER 5 YEARS FOLLOW UP AND RISK-STRATIFIED ANALYSIS

被引：0
|
作者：
Masi, G. [1 ]
Vasile, E. [1 ]
Loupakis, F. [1 ]
Cupini, S. [2 ]
Fornaro, L. [1 ]
Baldi, G. [2 ]
Salvatore, L. [1 ]
Stasi, I [1 ]
Brunetti, I [3 ]
Ricci, S. [3 ]
Palazzo, A. [4 ]
Pellegrino, A. [4 ]
Truscelli, K. [4 ]
Garrone, M. [5 ]
Chiara, S. [6 ]
Ribecco, A. [7 ]
Crino, L. [8 ]
Andreuccetti, M. [1 ]
Falcone, A. [1 ,2 ]
机构：
[1] Ist Toscano Tumori, Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy
[2] Ist Toscano Tumori, UO Oncol Med, Azienda USL Livorno 6, Livorno, Italy
[3] Ist Toscano Tumori, UO Oncol Med 1, Azienda Osped Univ Pisana, Pisa, Italy
[4] Univ Roma La Sapienza, UO Oncol B, Dipartimento Med Sperimentale, Rome, Italy
[5] Osped S Croce Carle, UO Oncol Med, Cuneo, Italy
[6] Ist Nazl Tumori, UO Oncol Med, Genoa, Italy
[7] Ist Toscano Tumori, Azienda Sanit Firenze, SC Oncol Med, Florence, Italy
[8] Osped S Andrea delle Fratte, UO Oncol Med, Perugia, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-minimization analysis of capecitabine plus oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting
    Perrocheau, G.
    Ducreux, M.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Faroux, R.
    Douillard, J. Y.
    Pacull, A.
    VALUE IN HEALTH, 2007, 10 (06) : A233 - A233
  • [22] Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC):: CALGB 80203 preliminary results.
    Venook, A.
    Niedzwiecki, D.
    Hollis, D.
    Sutherland, S.
    Goldberg, R.
    Alberts, S.
    Benson, A.
    Wade, J.
    Schilsky, R.
    Mayer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [23] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
    Falcone, Alfredo
    Ricci, Sergio
    Brunetti, Isa
    Pfanner, Elisabetta
    Allegrini, Giacomo
    Barbara, Cecilia
    Crino, Lucio
    Benedetti, Giovanni
    Evangelista, Walter
    Fanchini, Laura
    Cortesi, Enrico
    Picone, Vincenzo
    Vitello, Stefano
    Chiara, Silvana
    Granetto, Cristina
    Porcile, Gianfranco
    Fioretto, Luisa
    Orlandini, Cinzia
    Andreuccetti, Michele
    Masi, Gianluca
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1670 - 1676
  • [24] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Cost-minimization analysis of a phase III study of capecitabine plus oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting
    Perrocheau, G.
    Bennouna, J.
    Ducreux, M.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Adenis, A.
    Faroux, R.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] Biweekly administration of irinotecan (CPT-11), oxaliplatin (OX) and 5-fluorouracil (5-FU) as first-line treatment of advanced or metastatic colorectal cancer (MCRC)
    Reina, JJ
    Sánchez-Rovira, P
    Bernabé, R
    Bolaños, M
    González, E
    Belón, J
    Gómez-Reina, MJ
    Gallurt, P
    Moreno-Nogueira, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 260S - 260S
  • [27] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [28] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [29] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer
    Kopetz, S.
    Glover, K. Y.
    Eng, C.
    Wolff, R. A.
    Chang, D. Z.
    Adinin, R. B.
    Morris, J.
    Abbruzzese, J. L.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
    Masi, G
    Allegrini, G
    Cupini, S
    Marcucci, L
    Cerri, E
    Brunetti, I
    Fontana, E
    Ricci, S
    Andreuccetti, M
    Falcone, A
    ANNALS OF ONCOLOGY, 2004, 15 (12) : 1766 - 1772
12345